LLY · News · 20260901N
Mounjaro Cardiovascular Indication
ELI LILLY & Co · 2026-09-01 · Importance 47 · Surprise 60 · In source text
The FDA expanded Mounjaro’s label to include cardiovascular-risk reduction for patients with type 2 diabetes. The expanded indication gives Lilly a medical-necessity argument to support continued insurer reimbursement as employer coverage for GLP-1 weight-loss drugs declines. Mounjaro revenue grew significantly, with volume growth more than offsetting pricing declines. Lilly raised its full-year financial guidance following the product’s growth.
Key facts
- The FDA expanded the label for Eli Lilly's Mounjaro to include cardiovascular risk reduction in type 2 diabetes patients. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | The FDA expanded the label for Eli Lilly's Mounjaro to include cardiovascular risk reduction in type 2 diabetes patients. |